

# Myopia Control with Low-Dose Atropine in European Children: Six-Month Results from a Randomized, Double-Masked, Placebo-Controlled, Multicenter Study

Anders Hvid-Hansen <sup>1,\*</sup>, Nina Jacobsen <sup>1,2</sup>, Flemming Møller <sup>3</sup>, Toke Bek <sup>4</sup>, Brice Ozenne <sup>5,6</sup> and Line Kessel <sup>1,2</sup>

<sup>1</sup> Department of Ophthalmology, Copenhagen University Hospital—Rigshospitalet-Glostrup, DK-2600 Glostrup, Denmark

<sup>2</sup> Department of Clinical Medicine, University of Copenhagen, DK-2200 København N, Denmark

<sup>3</sup> Department of Ophthalmology, University Hospital of Southern Denmark—Vejle Hospital, DK-7100 Vejle, Denmark

<sup>4</sup> Department of Ophthalmology, Aarhus University Hospital, DK-8200 Aarhus N, Denmark

<sup>5</sup> Department of Public Health, Section of Biostatistics, University of Copenhagen, DK-1014 København K, Denmark

<sup>6</sup> Neurobiology Research Unit, Copenhagen University Hospital—Rigshospitalet, DK-2200 København N, Denmark

\* Correspondence: anders.johan.hvid-hansen@regionh.dk

**Table S1: Scheduled visits and examinations**

	Scree	Base	3 mo	6 mo	9 mo	12 mo	18 mo	24 mo	30 mo	36 mo
Slit lamp exam	X									
Dilated fundus exam	X									
Non-cycloplegic autoref.	X	X	X	X	X	X	X	X	X	X
Cycloplegic autoref.	X	X	X	X	X	X	X	X	X	X
Manifest refraction	X	X	X	X	X	X	X	X	X	X
Distance BCVA	X	X	X	X	X	X	X	X	X	X
Near BCVA		X	X	X	X	X	X	X	X	X
Accommodation amplitude		X	X	X	X	X	X	X	X	X
IOLMaster 700	X	(X)	X	X	X	X	X	X	X	X
Scheimpflug imaging	X	(X)	X	X	X	X	X	X	X	X
Pupillometry	X	(X)	X	X	X	X	X	X	X	X
SS-OCT		X	X	X	X	X	X	X	X	X
Intraocular pressure	X	(X)	X	X	X	X	X	X	X	X
Trial medication		X	X	X	X	X	X	X		
Compliance										
Registration of AR and AE		X	X	X	X	X	X	X	X	X

**Footnotes:** (X), optional examination if the period between screening and baseline was less than four weeks.

**Abbreviations:** AE = adverse events; AR = adverse reaction; autoref. = autorefraction; Base = Baseline; BCVA = best-corrected visual acuity; mo = months; Scree = screening; SS-OCT = swept-source optical coherence tomography.

**Table S2: Parental self-reported weekly compliance**

Compliance, N (%)	Treatment groups		
	Placebo	Low-dose (0.01% atropine)	Loading dose (0.1% to 0.01% atropine)
<b>At 3-month visit</b>			
N	32	32	33
6 days	1 (3.1)	1 (3.1)	3 (9.1)
7 days	31 (96.9)	31 (96.9)	30 (90.9)
<b>At 6-month visit</b>			
N	31	32	33
6 days	1 (3.2)	1 (3.1)	3 (9.1)
7 days	30 (96.8)	31 (96.9)	30 (90.9)

**Notes:** Weekly compliance as reported by the parents and presented as the number of days the trial medication was administered as prescribed during an average week since the last follow-up. No parents reported compliance below six days a week.

**Footnotes:** \*, adj-P < 0.05; \*\*, adj-P < 0.01; \*\*\*, adj-P < 0.001.

**Abbreviations:** N = number of participants.